UCB Wins Top Workplace
UCB Wins 2026 Metro Atlanta Top Workplaces Award for Thriving Employee Environment
UCB, a global biopharmaceutical company, has been named a winner of the 2026 Metro Atlanta Top Workplaces Award by Axios, according to PR Newswire. The award is based on employee feedback and reflects UCB's culture of collaboration, career growth, and meaningful work for patients with severe diseases.
The recognition adds to a big year for UCB in Georgia. Earlier in 2025, the company announced a $2 billion investment to build a new biomanufacturing campus in Gwinnett County. That project is expected to create more than 330 permanent, highly skilled jobs and generate an estimated $5 billion in economic impact, PR Newswire reported.
What the Top Workplaces Award Actually Measures
The Metro Atlanta Top Workplaces Award is not self-nominated. It is based entirely on employee surveys, according to Barchart. Workers rate their company on things like leadership, culture, and whether they feel their job matters. Companies do not win by applying — they win because their own employees say so.
For UCB, that feedback reflects a workplace built around a clear mission: improving the lives of people living with severe diseases. The company says it works to give employees room to grow, take on meaningful projects, and feel part of something bigger than a typical corporate job.
UCB's Deep Roots in Metro Atlanta Span 30 Years
UCB has kept its U.S. headquarters in metro Atlanta for more than 30 years. Today, the company employs over 400 people in Georgia, according to Yahoo Finance. That long-standing presence makes UCB one of the region's more established international biopharma employers.
The company is headquartered in Brussels, Belgium, but Atlanta has long served as its American hub. With operations spread across neurology and immunology treatments, UCB develops medicines for conditions like epilepsy, Parkinson's disease, and Crohn's disease.
$2 Billion Campus Signals Major Georgia Expansion
UCB's planned Gwinnett County biomanufacturing campus is one of the largest pharma investments in Georgia's recent history. The $2 billion project will produce biologics — complex medicines made from living cells. More than 330 permanent jobs are expected, with salaries likely well above state averages for manufacturing roles, according to PR Newswire.
The projected $5 billion economic impact figure accounts for jobs, local spending, and supply chain activity. The campus would strengthen Georgia's position as a growing hub for life sciences and advanced manufacturing, building on the state's existing base of biotech and pharmaceutical companies.
Why Workplace Culture Matters in the Biopharma Race for Talent
Biopharmaceutical companies compete fiercely for skilled scientists, engineers, and researchers. Winning a workplace award can help recruit top talent in a tight labor market. For UCB, being recognized in metro Atlanta — a fast-growing life sciences market — signals that it can attract and keep the workers it needs for its expansion plans.
UCB's timing is notable. The Top Workplaces win and the $2 billion campus announcement together paint a picture of a company investing heavily in both its people and its physical footprint in Georgia. Both moves point in the same direction: long-term commitment to the Atlanta region, according to PR Newswire.
Sentiment
NeutralPublishers
5
Articles
4
Reach
5
